nach oben

International Urogynecology Journal

Erschienen in:

01.12.2009 | Original Article

Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome

verfasst von: Peter K. Sand, Roger R. Dmochowski, Norman R. Zinner, David R. Staskin, Rodney A. Appell

Erschienen in: International Urogynecology Journal | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

To confirm the efficacy and tolerability of extended release (ER) trospium chloride in women with overactive bladder syndrome (OAB), data from two identical phase III studies were analyzed.

Methods

Adults (aged ≥ 18 years) who had OAB with urinary urgency, frequency, and urge urinary incontinence (UUI) were randomized to trospium ER 60 mg or placebo once daily for 12 weeks. The analysis included 989 women (trospium ER, n = 484; placebo, n = 505). Endpoints examined included changes from baseline in number of toilet voids and UUI episodes/day at week 12. Continuous data were analyzed using rank analysis of variance.

Results

At week 12, significantly greater mean reductions in numbers of toilet voids and UUI episodes/day occurred with trospium ER versus placebo (P < 0.0001). Adverse events considered at least possibly related to treatment with trospium ER included dry mouth (11.4%) and constipation (8.9%).

Conclusions

Trospium ER was effective and well tolerated in women with OAB.

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed

Dmochowski RR, Newman DK (2007) Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 23:65–76CrossRefPubMed

Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766CrossRefPubMed

Campbell UB, Stang P, Barron R (2007) Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 11:726–732CrossRefPubMed

Dmochowski RR, Sand PK, Zinner NR, Staskin DR (2008) Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 71:449–454CrossRefPubMed

Staskin D, Sand P, Zinner N, Dmochowski R (2007) Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 178:978–983CrossRefPubMed

Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski UE, Staskin DR et al (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604–607CrossRefPubMed

Zinner N, Harnett M, Sabounjian L, Sandage B Jr, Dmochowski R, Staskin D (2005) The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder. J Urol 173:1639–1643CrossRefPubMed

Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374–1379PubMed

10.

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574CrossRefPubMed

11.

Melville JL, Delaney K, Newton K, Katon W (2005) Incontinence severity and major depression in incontinent women. Obstet Gynecol 106:585–592PubMed

12.

Wilson L, Brown JS, Shin GP, Luc KO, Subak LL (2001) Annual direct cost of urinary incontinence. Obstet Gynecol 98:398–406CrossRefPubMed

13.

Wein AJ, Khullar V, Wang JT, Guan Z (2007) Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU Int 99:360–363CrossRefPubMed

14.

Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M (2006) Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 17:512–519CrossRefPubMed

15.

Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW (2003) Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62:237–242CrossRefPubMed

16.

Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M et al (2006) Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50:317–326CrossRefPubMed

17.

Staskin DR, Harnett MD (2004) Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 5:423–426CrossRefPubMed

18.

Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I (2005) Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 years. BJU Int 95:346–349CrossRefPubMed

19.

Todorova A, Vonderheid-Guth B, Dimpfel W (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41:636–644CrossRefPubMed

20.

Kay G, Malhotra B, Michel MC (2009) Assessment of central nervous system access of a new antimuscarinic drug, fesoterodine. J Urol 181(Suppl.):84CrossRef

21.

Sandage B, Lerch G, Larsen G, Profy A (2009) Trospium chloride does not cross the blood-brain barrier of male Long Evans rats. Neurology 72(Suppl 3):A50

22.

Geyer J, Gavrilova O, Petzinger E (2009) The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic OAB drug trospium chloride. Drug Metab Dispos 37(7):1371–1374CrossRefPubMed

23.

Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R (2006) Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 67:275–280CrossRefPubMed

24.

Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171:2311–2315 quiz 2435CrossRefPubMed

25.

Birns J, Lukkari E, Malone-Lee JG (2000) A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 85:793–798CrossRefPubMed

26.

Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A (2001) Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57:414–421CrossRefPubMed

27.

Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z (2007) Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 51:1054–1064CrossRefPubMed

28.

Swift S, Garely A, Dimpfl T, Payne C (2003) A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 14:50–54 discussion 54-55CrossRefPubMed

29.

van Leeuwen JH, Castro R, Busse M, Bemelmans BL (2006) The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 50:440–452CrossRefPubMed

30.

Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4:CD003781

Titel: Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome
verfasst von: Peter K. Sand
Roger R. Dmochowski
Norman R. Zinner
David R. Staskin
Rodney A. Appell
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: International Urogynecology Journal / Ausgabe 12/2009
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-009-0969-8

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2009

Is lysyl oxidase-like protein-1, alpha-1 antitrypsin, and neutrophil elastase site specific in pelvic organ prolapse?

“Commercial pressures and professional ethics: troubling revisions to the recent ACOG Practice Bulletins on surgery for pelvic organ prolapse”: response to Lawrence

Overactive bladder: a new paradigm

Are women with pelvic organ prolapse at a higher risk of developing hernias?

Foreign body reaction in vaginally eroded and noneroded polypropylene suburethral slings in the female: a case series

Pelvic floor muscle function in a general female population in relation with age and parity and the relation between voluntary and involuntary contractions of the pelvic floor musculature

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie